EntreMed Announces 2008 Corporate and Clinical Program ... (discovered and initially developed...)

EntreMed Announces 2008 Corporate and Clinical Program Priorities

Date:3/13/2008

discovered and initially

developed by Roche; EntreMed has an exclusive worldwide license to

develop and commercialize the drug.

-- MKC-1 is currently in multiple Phase 1 and Phase 2 clinical trials,

including metastatic breast cancer (MBC), non-small cell lung cancer

(NSCLC), hematological cancers, ovarian and endometrial cancer, and

pancreatic cancer. Milestones for MKC-1 in 2008 include reporting

results for the single agent MKC-1 MBC study (2Q08); presentation of

interim data for MKC-1/Alimta combination study in NSCLC (2Q08);

presentation of Phase 1 data for MKC-1 in hematological cancers (2H08);

initiation of a Phase 1 MKC-1 continuous dosing study (2Q08); and

presentation of interim data for a Phase 2 study in pancreatic cancer

(4Q08).

-- ENMD-1198 is a potent, orally-active, antimitotic agent discovered at

EntreMed that causes cell cycle arrest and apoptosis in tumor cells.

ENMD-1198 has shown pronounced antitumor activity and survival

increases in multiple preclinical models, including a substantial

decrease in tumor cell proliferation and angiogenesis in a breast

cancer model; synergistic effects in combination with vincristine that

prolonged survival in preclinical leukemia models; and a three-fold

increase in survival compared to standard-of-care Cisplatin in a

preclinical NSCLC model.

-- A Phase 1b dose-escalation clinical trial is currently underway to

evaluate ENMD-1198 in patients with refractory solid tumors. Completion

of the study is expected around mid-2008 with a further trial expected

in the second half of 2008. ENMD-1198 milestones for 2008 include

completion of Phase 1b enrollment (2Q/3Q08); initiation of an expanded

Phase 1 or Phase 2 trial (3Q/4Q08); and the reporting of data for the

Phase 1b clinical
'/>"/>

Post Your Comments:

EntreMed Announces 2008 Corporate and Clinical Program ...(discovered and initially developed...)